Email this article Comparative efficacy of different therapeutic schemes in gastropathies provoked by nonsteroid anti-inflammatory drugs
- Authors: Maev IV1, Vyuchnova ES1, Staseva IV1
-
Affiliations:
- Issue: Vol 79, No 2 (2004)
- Pages: 27-30
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/29749
- ID: 29749
Cite item
Full Text
Abstract
Aim. To study efficacy of colloid bismuth subcitrate (de-nol, Yamanuchi) in therapy of gastropathies provoked by nonsteroidal anti-inflammatory drugs (NSAID).
Material and methods. 63 patients (38 women and 25 men, mean age 54.2 ± 12.8 years) with rheumatoid arthritis (n = 14), osteoarthrosis (n = 47), gouty arthritis (n = 2) regularly taking NSAID were examined. The patients were randomized into two groups. The patients of the control group 1 received therapy with omeprasol (40 mg/day), patients of group 2 were given omeprasol (40 mg/day) and de-nol (480 mg/day).
Results. Epithelization of erosive-ulcerous lesions were observed on the treatment day 28 in 93.9% patients of group 1 and all the patients of group 2. Normalization of the level of prostaglandin E, by the end of the treatment was registered in 57% and 93.3% patients of groups 1 and 2, respectively. Conclusion. Colloid bismuth subcitrate (de-nol) effectively improves the condition of NSAID gastropathy patients, stimulates healing of erosive-ulcerous lesions of gastroduodenal zone in elevation of prostaglandins levels.
Material and methods. 63 patients (38 women and 25 men, mean age 54.2 ± 12.8 years) with rheumatoid arthritis (n = 14), osteoarthrosis (n = 47), gouty arthritis (n = 2) regularly taking NSAID were examined. The patients were randomized into two groups. The patients of the control group 1 received therapy with omeprasol (40 mg/day), patients of group 2 were given omeprasol (40 mg/day) and de-nol (480 mg/day).
Results. Epithelization of erosive-ulcerous lesions were observed on the treatment day 28 in 93.9% patients of group 1 and all the patients of group 2. Normalization of the level of prostaglandin E, by the end of the treatment was registered in 57% and 93.3% patients of groups 1 and 2, respectively. Conclusion. Colloid bismuth subcitrate (de-nol) effectively improves the condition of NSAID gastropathy patients, stimulates healing of erosive-ulcerous lesions of gastroduodenal zone in elevation of prostaglandins levels.
References
- Graham D. Y. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am. J. Gastroenterol. 1996; 91: 2800-2806.
- Griffin M. R. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am. J. Med. 1998; 104 (ЗА): 23S-29S.
- Насонов Е. Л., Каратеев А. Е. Поражения желудка, связанные с приемом нестероидных противовоспалительных препаратов. Клин. мед. 2000; 3: 4-10; 4: 4-9.
- Garsia Rodriguez L. A. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am. J. Med. 1998; 104 (ЗА): 30S-34S.
- Аруин А. Л., Капуллер Л. Л., Исаков В. А. Морфологическая диагностика заболеваний желудка и кишечника. М.: Триада-Х; 1998.
- Paulus H. E. FDA Arthritis Advisory Committee meeting: postmarketing surveillance of nonsteroidal anti-inflammatory drugs. Arthr. and Rheum. 1985; 28: 1168-1169.
- Hall D. W., van den Hoven W. E. Gastric mucosa protection and prostaglandin E2 generation in rats by colloidal bismuth substrate (DE-NOL). Arch. Int. Pharmacodyn. Ther. 1087; 286 (2): 308-319.
- Konturek S. J., Radecki Т., Piastucki I. Studies on the gastroprotective and ulcerhealing affects of colloidal bismuth substrate. Digestion 1987;37 (suppl. 2): 8-15.
- Konturek S. J., Radecki Т., Piastucki I. et al. Gastroprotection by colloidal bismuth substraty (De-Nol) and sucralfate. Role of endogenous prostaglandins. Gut 1987; 28 (2): 201-205.
- Konturek S. J., Bilski J., Kwiecien N. et al. De-Nol stimulates gastric and duodenal alkaline secretion through prostaglandin dependent mechanism. Gut 1987; 28 (12): 1557-1563.
- Piotrowski J., Bilski J., Nishikawa H. et al. Enhancement in gastric mucus gel qualities with colloidal bismuth substrate administration. Eur. J. Pharmacol. 1990; 184 (1): 55-63.
- Slomiany B. L., Nishikawa H., Bilski J. Slomiany A. Collodial bismuth substrate inhibits peptic degradation of gastric mucus and epidermal growth factor in vitro. Am. J. Gastroenterol. 1990; 85 (4): 390-393.
- Koo J., Ho J., Lam S. K. et al. Selective coating of gastric ulcer by tripotassium dicitrato bismuthate in the rat. Gastroenterology 1982; 82 (5, pt 1): 864-870.
Supplementary files
